MeiraGTx's Parkinson's gene therapy shows promise in Phase I/II study [Yahoo! Finance]
MeiraGTx Holdings plc - Ordinary Shares (MGTX)
Company Research
Source: Yahoo! Finance
The sham-controlled bridging study evaluated the company's AAV-GAD therapy over 26 weeks in 14 patients across three arms, high-dose, low-dose and a sham control. At week 26, the high dose group was found to have a statistically significant 18-point average improvement in their ‘off' score on the Movement Disorder Society – Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III Parkinson's disease measurement score. In the 15 October announcement, Alexandria Forbes, president and CEO of MeiraGTx said “a change of five to 10 points is considered clinically meaningful". She added: “The 18-point change observed in the high dose arm in this study underscores the very substantial impact of AAV-GAD treatment in these Parkinson's patients.” The high- and low-dose groups were each made up of five patients, while the sham group consisted of four. The low-dose and sham groups saw no significant change in their score, but the primary endpoint of safety and tolerability was met. Spe
Show less
Read more
Impact Snapshot
Event Time:
MGTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MGTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MGTX alerts
High impacting MeiraGTx Holdings plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
MGTX
News
- Latest Published 5 Rare Eye Diseases Market Reports by DelveInsight: Retinitis Pigmentosa, Stargardt Disease, Ocular Melanoma, Uveitis, and Neurotrophic Keratitis [Yahoo! Finance]Yahoo! Finance
- Investors in MeiraGTx Holdings (NASDAQ:MGTX) have unfortunately lost 71% over the last five years [Yahoo! Finance]Yahoo! Finance
- MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced XerostomiaGlobeNewswire
- Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive DirectorsPR Newswire
- MeiraGTx Holdings plc (NASDAQ: MGTX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $36.00 price target on the stock.MarketBeat
MGTX
Earnings
- 11/13/24 - Miss
MGTX
Sec Filings
- 12/9/24 - Form 8-K
- 11/13/24 - Form 10-Q
- 11/13/24 - Form 8-K
- MGTX's page on the SEC website